---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-040885"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T21:44:15.155369+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vaccinex enters 8 ActivMAb agreements including 3 major pharma companies for complex membrane targets

## Summary
- Eight new antibody discovery agreements integrate ActivMAb platform, with 3 major pharma/biotech companies and 5 strategic antibody-service partners.
- ActivMAb 'Antigen Virus' application targets difficult multi-pass membrane proteins such as GPCRs, ion channels, and chemokine receptors.
- Technology enables antibody drug conjugate (ADC) development for cancer; platform uses purified viral presentation for efficient selection.
- Agreements signed within last 3 months; CEO cites renewed market optimism after two-year biotech downturn as driver of interest.

## SEC filing metadata
- accession: 0001193125-24-040885
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312524040885/0001193125-24-040885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312524040885/d781705d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-040885
- JSON: https://secwatch.observer/filing/0001193125-24-040885.json
- Plain text: https://secwatch.observer/filing/0001193125-24-040885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.